DrugPatentWatch Database Preview

Details for Patent: 8,858,996

« Back to Dashboard

Which drugs does patent 8,858,996 protect, and when does it expire?

Patent 8,858,996 protects VIMOVO and is included in one NDA.

This patent has thirty-seven patent family members in twenty-two countries.

Summary for Patent: 8,858,996

Title:	Pharmaceutical compositions for the coordinated delivery of NSAIDS
Abstract:	The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
Inventor(s):	Plachetka; John R. (Chapel Hill, NC)
Assignee:	Pozen Inc. (Chapel Hill, NC)
Application Number:	14/244,471
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,858,996
Patent Claim Types: see list of patent claims	Composition; Dosage form; Use;

Drugs Protected by US Patent 8,858,996

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Horizon	VIMOVO	esomeprazole magnesium; naproxen	TABLET, DELAYED RELEASE;ORAL	022511-002	Apr 30, 2010	AB	RX	Yes	No			Y
Horizon	VIMOVO	esomeprazole magnesium; naproxen	TABLET, DELAYED RELEASE;ORAL	022511-001	Apr 30, 2010	AB	RX	Yes	Yes			Y

International Family Members for US Patent 8,858,996

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	474559
Australia	2002305758
Australia	2006235929